General
Preferred name
PALIPERIDONE
Synonyms
Ro-92670 ()
Invega Sustenna ()
9-hydroxyrisperidone ()
9-OH-risperidone ()
paliperidone ER, Torrent Pharmaceuticals ()
Ro-76477 ()
NSC-759623 ()
Risperidone impurity, 9-hydroxyrisperidone- ()
Invega ()
Paliperidona ()
R-76477 ()
RO76477 ()
Paliperidone-d4 ()
Paliperidone (CRM) ()
P&D ID
PD009928
CAS
144598-75-4
130049-84-2
1020719-55-4
Tags
available
drug
Approved by
FDA
EMA
First approval
2006
Drug indication
Schizophrenia
Schizoaffective disorder
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Paliperidone is an atypical antipsychotic developed by Janssen Pharmaceutica. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone). The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone.
DESCRIPTION Paliperidone is an atypical antipsychotic. Mechanistically it is a dopamine receptor and 5-HT2A receptor antagonist. (GtoPdb)
PRICE 29
DESCRIPTION Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at ¦Á1 and ¦Á2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1].
DESCRIPTION 5-HT2C inverse agonist; alpha2-adrenoceptor antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Paliperidone is an atypical antipsychotic used in the treatment of schizophrenia and other schizoaffective or delusional disorders. (Enamine Bioactive Compounds)
DESCRIPTION Paliperidone (9-hydroxyrisperidone)(Invega) is used as an atypical antipsychotic. It applies to the acute and maintenance treatment of schizophrenia. Chemically, paliperidone is the primary active metabolite of the older atypical antipsychotic risperidone. (TargetMol Bioactive Compound Library)
Compound Sets
27
AdooQ Bioactive Compound Library
A10691
Cayman Chemical Bioactives
15556
40387
28484
ChEMBL Approved Drugs
CHEMBL1621
ChEMBL Drugs
CHEMBL1621
CZ-OPENSCREEN Bioactive Library
DrugBank
DB01267
DrugBank Approved Drugs
DB01267
DrugCentral
4137
DrugCentral Approved Drugs
4137
DrugMAP
DM7NPJS
DrugMAP Approved Drugs
DM7NPJS
Enamine Bioactive Compounds
EBC-13192
Enamine BioReference Compounds
Guide to Pharmacology
7258
JUMP-Target 1 Compound Set
115237
Ki Database
9-OH-risperidone
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1621
MedChem Express Bioactive Compound Library
HY-A0019
NCATS Inxight Approved Drugs
838F01T721
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Paliperidone(Invega)
TargetMol Bioactive Compound Library
T0076
Tocris Bioactive Compound Library
4493
VGSC-DB
NA0102
NA0103
External IDs
47
Properties
(calculated by RDKit )
Molecular Weight
426.21
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
3
cLogP
3.08
TPSA
84.39
Fraction CSP3
0.52
Chiral centers
1.0
Largest ring
6.0
QED
0.69
QED
0.69
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Metabolic Enzyme/Protease
Neuronal Signaling
Primary Target
5-HT2A Receptors
MOA
Antagonist
Target
HTR2C
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
Drug Metabolite
5-HT
dopamine
H1 receptor
β-adrenergic receptor
VGSC Target
Nav1.5
Source data